Citation: | Min Pei, Tingting Liu, Lu Ouyang, Jianhua Sun, Xiaojie Deng, Xiaomin Sun, Wei Wu, Peng Huang, Yi-Li Chen, Xiaorong Tan, Xiaoyue Liu, Peng Zhu, Yongzhen Liu, Deheng Wang, Junliang Wu, Qi Wang, Guifeng Wang, Likun Gong, Qiuping Qin, Chunhe Wang. Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera[J]. Journal of Pharmaceutical Analysis, 2022, 12(4): 645-652. doi: 10.1016/j.jpha.2021.11.005 |
P. Khongorzul, C.J. Ling, F.U. Khan, et al., Antibody-Drug Conjugates:A Comprehensive Review, Mol. Cancer Res. 18 (2020) 3-19
|
E.L. Sievers, P.D. Senter, Antibody-drug conjugates in cancer therapy, Annu. Rev. Med. 64 (2013) 15-29
|
S.C. Alley, N.M. Okeley, P.D. Senter, Antibody-drug conjugates:targeted drug delivery for ca- ncer, Curr. Opin. Chem. Biol. 14 (2010) 529-537
|
N. Joubert, A. Beck, C. Dumontet, et al., Antibody-Drug Conjugates:The Last Decade, Pharmaceuticals (Basel) 13 (2020), 245
|
C.H. Chau, P.S. Steeg, W.D. Figg, Antibody-drug conjugates for cancer, Lancet. 394 (2019) 793-804
|
P. Zuo, Capturing the Magic Bullet:Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates, AAPS J. 22 (2020), 105
|
A. Khot, S. Sharma, D. K. Shah, Integration of bioanalytical measurements using PK-PD modeling and simulation:implications for antibody-drug conjugate development, Bioanalysis. 7 (2015) 1633-1648
|
J.P. Stephan, K.R. Kozak, W.L.T. Wong, Challenges in developing bioanalytical assays for ch- aracterization of antibody-drug conjugates, Bioanalysis. 3 (2011) 677-700
|
K. Surinder, K. Xu, O.M. Saad, et al., Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics, Bioanalysis. 5 (2013) 201-226
|
J. Katz, J.E. Janik, A. Younes, Brentuximab Vedotin (SGN-35), Clin. Cancer Res. 17 (2011) 6428-6436
|
B.A. Teicher, R.V.J. Chari, Antibody Conjugate Therapeutics:Challenges and Potential, Clin. Cancer Res. 17 (2011) 6389-6397
|
K. Inamura, Y. Yokouchi, M. Kobayashi, et al., Association of tumor TROP2 expression with prognosis varies am- ong lung cancer subtypes, Oncotarget. 8 (2017) 28725-28735
|
T. Ohmachi, F. Tanaka, K. Mimori, et al., Clinical Significance of TROP2 Expression in Colorectal Cancer, Clin. Cancer Res. 12 (2006) 3057-3063
|
S.V. Govindan, Z. Qu, H.J. Hansen, et al., inventors; RS7 antibodies. United States patent US8758752B2. 24 June 2014
|
C. Wang, P. Huang, L. Chen, et al., inventors; Target the antibody of TACSTD2 and drug coupling body (ADC) molecule. Chinese Patent CN108066772A. 14 November 2016
|
Y.-L. Chen, X. Tan, C. Wang, et al., inventors; Anti-MMAE monoclonal antibody, coding sequence and application thereof. Chinese Patent CN112457406A. 27 November 2020
|
B.-Q. Shen, K. Xu, L. Liu, et al., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates, Nat. Biotechnol. 30 (2012) 184-189
|
R.J. Sanderson, M.A. Hering, S.F. James, et al., In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate, Clin. Cancer Res. 11(2 Pt 1) (2005) 843-852
|